KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2025)

Royalty Pharma's Cash from Investing Activities history spans 6 years, with the latest figure at -$847.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 67.69% year-over-year to -$847.8 million; the TTM value through Dec 2025 reached -$2.0 billion, up 23.75%, while the annual FY2025 figure was -$1.6 billion, 39.73% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$847.8 million at Royalty Pharma, down from $503.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $503.9 million in Q1 2025 and bottomed at -$1.4 billion in Q3 2022.
  • The 5-year median for Cash from Investing Activities is -$528.6 million (2021), against an average of -$409.0 million.
  • The largest annual shift saw Cash from Investing Activities crashed 5102.47% in 2023 before it skyrocketed 681.55% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$551.6 million in 2021, then skyrocketed by 175.18% to $414.7 million in 2022, then tumbled by 115.29% to -$63.4 million in 2023, then plummeted by 697.04% to -$505.6 million in 2024, then tumbled by 67.69% to -$847.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Cash from Investing Activities are -$847.8 million (Q4 2025), $503.9 million (Q1 2025), and -$505.6 million (Q4 2024).